FDA has issued draft guidance describing the agency’s current thinking on several topics relevant to clinical research related to the development of drugs containing cannabis or cannabis-derived compounds.
Similar Posts
State Importation Program Enhancements
FDA is committed to continuing to work with states and Indian tribes that seek to develop an importation proposal under section 804 of the Federal Food, Drug and Cosmetic Act.Revitalize Energy, Inc. – 712417 – 07/09/2025
Unapproved New Drugs/MisbrandedWorld Market Recalls Emek Spread Pistachio Cacao Cream with Kadayif Due to Salmonella Contamination
World Market is recalling EMEK SPREAD PISTACHIO CACAO CREAM WITH KADAYIF, 9.7oz, Best Before: April 01, 2027, Batch Number: 250401 due to a potential contamination of Salmonella. Salmonella is an organism which can cause serious and sometimes fatal infections in young children, frail or elderlyFDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process
By clarifying FDA’s regulatory expectations for new entrants and experienced drug developers alike, FDA is supporting prospective generic drug developers and improving the overall quality of ANDAs submitted to the Agency for approval.Early Alert: Microbore Extension Set Issue from B. Braun Medical Inc.
This communication is part of the Communications Pilot to Enhance the Medical Device Recall ProgramAbsolutely Natural – 715690 – 12/30/2025
CGMP/Finished Pharmaceuticals/Adulterated